Eagle Pharmaceuticals, Inc.
EGRX · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -2.5% | 9.2% | -7.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 73.9% | 73.9% | 67.3% | 64.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 15.9% | 9.3% | 15.6% | -3.5% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 8% | 8.7% | 13.5% | -5.3% |
| EPS | 0.39 | 0.44 | 0.63 | -0.27 |
| % Growth | -11.4% | -30.2% | 333.3% | – |
| EPS Diluted | 0.39 | 0.44 | 0.62 | -0.27 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 25.3% | 26.1% | 34.9% | 3.3% |